• Gabi’s Gift (CAPRISA 004 Video)

    This five-minute video follows one woman from the beginning of her participation in the CAPRISA 004 study of tenofovir gel to her joy when hearing the results.

  • MTN-017

    Links are provided to information about MTN-017. The first Phase II trial of a rectal microbicide, MTN-017 found that a reduced-glycerin formulation of tenofovir gel was safe when used daily and before and after sex. Study participants were just as likely to follow through using an anti-HIV gel with anal sex as they were to using daily oral pre-exposure prophylaxis (PrEP).

  • AIDS 2010: July 20, 2010: Results of the CAPRISA 004 Trial

    Dr. Salim Abdool Karim of CAPRISA announces the results of the CAPRISA 004 trial in this 70-minute video. The results, which showed proof-of-concept for microbicides, were presented in the International AIDS Conference 2010 session "Safety and Effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial."  A link for accessing a transcript of the session is provided.

  • Acceptability of Vaginal Film, Soft-gel Capsule, and Tablet as Potential Microbicide Delivery Methods among African Women (abstract)

    A total of 526 sexually active women ages 18 to 30 years participated in a consumer product preference study in Burkina Faso, Tanzania, and Zambia. The women were asked to use each of three products (placebo formulations of a vaginal tablet, film, and soft-gel capsule) once daily for seven consecutive days for a total of 21 days. Data suggest that the availability of microbicides in multiple dosage forms may increase acceptability and adherence and, therefore, effectiveness. This abstract summarizes an eight-page paper published in the Journal of Women's Health.

  • Acceptability and Adherence of a Candidate Microbicide Gel among High-Risk Women in African and India

    A 15-page paper, published in Culture, Health & Sexuality, examines qualitative, in-depth post-trial interview data from a Phase III clinical trial of cellulose sulfate microbicide gel in two sites in Africa (Uganda and Benin) and two in India (Chennai and Bagalkot) to better understand the factors that influence microbicide acceptability and adherence in a clinical trial setting.